Why the study?
Decreasing clinical use and costly production and preservation of 133Xenon make alternative non-invasive methods to measure adipose tissue blood flow necessary.
Can percutaneous Doppler ultrasound be used as a proxy method to quantify intravascular subcutaneous abdominal and femoral adipose tissue blood flow in healthy individuals?
Can percutaneous Doppler ultrasound be used as a proxy method to quantify intravascular subcutaneous abdominal and femoral adipose tissue blood flow in healthy individuals?
Percutaneous Doppler ultrasound is a feasible non-invasive method to quantify intravascular subcutaneous adipose tissue blood flow, successfully detecting expected depot-differences and postprandial increases.
Supports non-invasive ATBF quantification by Doppler ultrasound; leaves open validation in disease states before research adoption.
Adipose tissue blood flow (ATBF) is an important determinant of adipose tissue (AT) function. 133Xenon wash-out technique is considered the gold-standard for human ATBF measurements. However, decreasing 133Xenon clinical use and costly production and preservation, make alternative (non-invasive) methods necessary. Here, we explored percutaneous Doppler ultrasound as a proxy method to quantify intravascular subcutaneous abdominal and femoral ATBF in humans (n= 17). Both fasting ATBF and the postprandial increase in ATBF were significantly higher in abdominal compared to femoral AT. Although anatomical variations in vein location and depot thickness may impact feasibility, we demonstrate that Doppler ultrasound detects the expected depot-differences and postprandial increase in ATBF in healthy individuals. This method warrants further investigation in other populations and metabolic conditions.
No takes yet. Share an insight, caveat, or question.
Lempesis et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: